{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-001112","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.684864+00:00","generated_at":"2026-05-28T09:22:25.597147+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Telomir-1 restores lifespan to near-normal in preclinical progeria model","bullets":["In C. elegans with wrn-1 mutation (Werner Syndrome model), Telomir-1 restored lifespan to near-normal levels.","Progeria causes rapid aging in children; these results suggest potential for Telomir-1 to address cellular aging issues.","Telomir Pharmaceuticals (Nasdaq: TELO) announced the findings in an SEC filing on Jan 7, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-001112","json":"https://secwatch.observer/filing/0001493152-25-001112.json","markdown":"https://secwatch.observer/filing/0001493152-25-001112.md","text":"https://secwatch.observer/filing/0001493152-25-001112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225001112/0001493152-25-001112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225001112/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T09:22:25.597147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}